Skin injuries associated with biological therapy in inflammatory bowel disease : beyond psoriasis
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Gastroenterologia y hepatologia - 45(2022), 1 vom: 10. Jan., Seite 62-63 |
| Sprache: |
Englisch |
|---|
| Weiterer Titel: |
Lesiones cutáneas con fármacos biológicos en la enfermedad inflamatoria intestinal: más allá de la psoriasis |
|---|
| Beteiligte Personen: |
Mínguez Sabater, Alejandro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9RV78Q2002 |
|---|
| Anmerkungen: |
Date Completed 14.02.2022 Date Revised 14.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.gastrohep.2020.09.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317568302 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317568302 | ||
| 003 | DE-627 | ||
| 005 | 20231225163535.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.gastrohep.2020.09.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1058.xml |
| 035 | |a (DE-627)NLM317568302 | ||
| 035 | |a (NLM)33189407 | ||
| 035 | |a (PII)S0210-5705(20)30378-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mínguez Sabater, Alejandro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Skin injuries associated with biological therapy in inflammatory bowel disease |b beyond psoriasis |
| 246 | 3 | 3 | |a Lesiones cutáneas con fármacos biológicos en la enfermedad inflamatoria intestinal: más allá de la psoriasis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2022 | ||
| 500 | |a Date Revised 14.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Case Reports | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Gastrointestinal Agents |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor Inhibitors |2 NLM | |
| 650 | 7 | |a vedolizumab |2 NLM | |
| 650 | 7 | |a 9RV78Q2002 |2 NLM | |
| 650 | 7 | |a Adalimumab |2 NLM | |
| 650 | 7 | |a FYS6T7F842 |2 NLM | |
| 700 | 1 | |a Martínez Delgado, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Ladrón Abia, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Bastida, Guillermo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastroenterologia y hepatologia |d 1993 |g 45(2022), 1 vom: 10. Jan., Seite 62-63 |w (DE-627)NLM075187280 |x 0210-5705 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2022 |g number:1 |g day:10 |g month:01 |g pages:62-63 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.gastrohep.2020.09.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2022 |e 1 |b 10 |c 01 |h 62-63 | ||